Cardiovascular disease is the leading cause of death in Sweden and worldwide. Therefore the WHO has a programme on Cardiovascular Diseases that works on prevention, management and monitoring of cardiovascular disease globally. It aims to develop global strategies to reduce the incidence, morbidity and mortality of cardiovascular diseases. CPE have selected cardiovascular pharmacoepidemiology as one area of interest because many people in the population uses drugs that prevent or treat cardiovascular diseases.
Cardiovascular pharmacoepidemiology includes research concerning all drugs used for prevention or treatment of cardiovascular events, such as antithrombotic and lipid lowering drugs. It may also include cardiovascular outcomes such as acute myocardial infarction and stroke as side effects from other drugs.
Researchers at CPE are involved in several studies focusing on drugs used for preventing or treating cardiovascular events. In particular we have studied lipid lowering drugs and antithrombotic drugs. Other important areas in which CPE researchers are involved include cardiovascular outcomes as side effects from other drugs.
Considering that adverse effects of drug use are rare events, very large sample sizes are necessary to assure detection of these events. Accordingly, and to ensure generalizability, many of our studies are done in collaboration with research partners around the world and including data from various databases.
Read more about cardiovascular diseases at WHO.
The research area is led by Marie Linder (Publications on PubMed)